RRM1的SNP与维汉两民族NSCLC患者对含吉西他滨化疗方案敏感性的相关性研究

发布时间：2018-04-23 15:31

本文选题：维吾尔族 + 非小细胞肺癌　；参考：《石河子大学》2017年硕士论文

【摘要】：目的:通过测定维吾尔族及汉族NSCLC患者RRM1的SNP状态,分析RRM137及524位点SNP在维汉两民族NSCLC患者的差异性,为维吾尔族NSCLC患者的个体化治疗提供一定的科学依据。方法:收集我院和喀什地区第一人民医院维吾尔族及汉族NSCLC患者共110例(其中维吾尔族51例,汉族59例),提取外周血DNA,通过多聚酶链反应-限制性片段长度多态性(Polymerase chain reaction-Restrietion fragment lengthpolymorphism,PCR-RFLP)方法检测RRM137位点SNP,直接测序法检测RRM1524位点SNP,分析维吾尔族及汉族在RRM137及524位点基因型构成的差异性,并进一步分析RRM137及524位点SNP与两民族NSCLC患者使用含吉西他滨化疗方案敏感性的相关性。结果:1.在使用含吉西他滨治疗方案的维吾尔族NSCLC患者中,RRM137CC及RRM1524CT基因型对含吉西他滨化疗方案敏感性最高,差异有统计学意义(P=0.011,P=0.007);汉族NSCLC患者中RRM137AC及RRM1524CT基因型对含吉西他滨化疗方案敏感性最高,差异有统计学意义(P=0.021,P=0.014)。2.维吾尔族及汉族使用含吉西他滨化疗方案的NSCLC患者在RRM137及524位点的SNP构成上无显著差异(P0.05)。3.维吾尔族及汉族NSCLC患者的性别、年龄、吸烟与否、临床分期、病理类型及ECOG评分与含吉西他滨化疗方案敏感性之间均无显著性差异(P0.05)。结论:1.维吾尔族与汉族NSCLC患者RRM137位点不同SNP使用含吉西他滨化疗方案敏感性不同,维吾尔族NSCLC患者RRM137位点CC基因型使用含吉西他滨化疗方案敏感性更高,汉族NSCLC患者RRM137AC基因型使用含吉西他滨化疗方案敏感性更高。2.维吾尔族与汉族NSCLC患者RRM1524位点不同SNP使用含吉西他滨化疗方案敏感性相同,均表现为RRM1524CT基因型使用含吉西他滨化疗方案敏感性更高。3.维吾尔族和汉族NSCLC患者在RRM137及524位点的SNP构成相似。
[Abstract]:Objective: to determine the SNP status of RRM1 in NSCLC patients of Uygur and Han nationality, and to analyze the difference of RRM137 and 524 locus SNP in NSCLC patients of Uygur and Han nationalities, so as to provide scientific basis for individualized treatment of NSCLC patients in Uygur nationality. Methods: a total of 110 patients with NSCLC in Uygur and Han nationality were collected from our hospital and the first people's Hospital of Kashgar region (51 cases of Uygur nationality). Peripheral blood DNA was extracted from 59 cases of Han nationality. RRM137 locus was detected by polymerase chain reaction-restriction fragment length polymorphism (Polymerase chain reaction-Restrietion fragment length polymorphism RFLP), RRM1524 locus was detected by direct sequencing, and RRM137 and 524 loci were analyzed in Uygur and Han nationality. The difference in the composition of factors, The relationship between RRM137 and 524 locus SNP and sensitivity to gemcitabine chemotherapy regimen in patients with NSCLC was further analyzed. The result is 1: 1. In Uygur NSCLC patients with gemcitabine regimen, RRM137CC and RRM1524CT genotypes were most sensitive to gemcitabine regimen. The difference was statistically significant in RRM137AC and RRM1524CT genotypes in patients with NSCLC. The sensitivity of RRM137AC and RRM1524CT genotypes to gemcitabine regimen was the highest, and the difference was statistically significant (P < 0.05). There was no significant difference in SNP composition of RRM137 and 524 locus between Uygur and Han people using gemcitabine chemotherapy regimen (P0.05. 3). There was no significant difference in sex, age, smoking, clinical stage, pathological type, ECOG score and sensitivity of gemcitabine chemotherapy regimen between Uygur and Han nationality patients (P 0.05). Conclusion 1. The sensitivity of SNP with gemcitabine was different between Uygur and Han NSCLC patients. CC genotype of RRM137 locus was more sensitive to gemcitabine in Uygur NSCLC patients. RRM137AC genotypes of NSCLC patients in Han nationality were more sensitive to gemcitabine chemotherapy regimen. 2. 2. The sensitivity of different RRM1524 loci in Uygur and Han NSCLC patients using gemcitabine chemotherapy regimen was the same, and the sensitivity of RRM1524CT genotypes to gemcitabine regimen was higher. 3. The SNP composition of RRM137 and 524 loci in Uygur and Han NSCLC patients were similar.
【学位授予单位】：石河子大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2

【参考文献】